SAN CARLOS, CALIFORNIA, April 29, 2026
Earflo has announced the FDA clearance and U.S. market availability of its innovative non-invasive pediatric ear pressure treatment device, offering a breakthrough at-home solution for children suffering from negative middle ear pressure and fluid buildup. This condition, commonly associated with otitis media with effusion (OME), affects millions of children globally and is a leading cause of hearing issues and surgical intervention. The newly cleared device represents a significant advancement in pediatric MedTech, providing families with a safe, effective alternative to invasive ear tube surgery, which remains one of the most common pediatric procedures in the United States.
Non-Invasive Innovation Targets Common Pediatric Condition
The Earflo device is designed to deliver a precisely controlled puff of air through the nasal passage into the eustachian tube, helping to equalize pressure in the middle ear and reduce fluid accumulation. This mechanism directly addresses the underlying cause of OME, enabling natural drainage and improved ear function. Unlike traditional treatment approaches that rely on a “watchful waiting” period, where symptoms persist and may worsen, Earflo empowers parents with a proactive, home-based treatment option.
The device is paired with a smart mobile application, which guides therapy sessions, tracks usage, and uses gamified engagement tools to encourage consistent use among children. This integration of digital health technology with medical-grade therapy enhances both treatment adherence and clinical outcomes, making it a compelling solution in modern pediatric care.
Clinical Evidence Demonstrates Strong Outcomes
Advertisement
Clinical studies supporting the Earflo device demonstrate high efficacy and safety, reinforcing its value as a non-surgical therapeutic alternative. Research findings indicate that 86% of children experienced immediate improvement in middle ear pressure, while 86% showed significant hearing improvement after four weeks of use. Notably, 89% of children were able to avoid surgical intervention, highlighting the device’s potential to reduce healthcare burden and improve quality of life for pediatric patients.
Given that approximately 90% of children experience OME by the age of five, and nearly one million ear tube surgeries are performed annually in the U.S., the availability of a clinically validated, non-invasive treatment marks a transformative shift in managing this widespread condition.
Award-Winning Design and Market Expansion Strategy
Earflo’s innovation has gained widespread recognition, earning prestigious honors such as TIME Best Inventions of 2025 and the CES Innovation Awards® Best of Innovation in Digital Health, reflecting its cutting-edge design and clinical impact. The device’s child-friendly form factor, combined with advanced engineering and intuitive usability, ensures both comfort and effectiveness during therapy sessions. Backed by mission-driven investments from organizations such as the Richard King Mellon Foundation and the Eye and Ear Foundation of Pittsburgh, Earflo is well positioned to scale its technology and expand accessibility.
With FDA clearance secured, the company plans to distribute the device through pediatric healthcare providers and consumer channels, making this innovative ear care solution widely available to families. From a regulatory standpoint, the product adheres to strict medical device compliance standards, including Good Manufacturing Practice (GMP), ensuring quality, safety, and reliability in clinical use. As healthcare continues to shift toward patient-centric, at-home treatment models, Earflo stands at the forefront of MedTech innovation, offering a practical, scalable solution that reduces reliance on surgery while improving pediatric outcomes.
Source: Earflo press release
